 Steven Bair
Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 8 | 2023 | 134 | 2.760 |
Why?
| | Immunotherapy, Adoptive | 5 | 2024 | 295 | 1.440 |
Why?
| | Antineoplastic Agents, Immunological | 3 | 2025 | 181 | 1.230 |
Why?
| | Immunoconjugates | 4 | 2025 | 103 | 1.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2020 | 573 | 0.940 |
Why?
| | Radiopharmaceuticals | 1 | 2019 | 168 | 0.600 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2019 | 64 | 0.600 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2019 | 129 | 0.590 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 140 | 0.580 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 3 | 2025 | 112 | 0.570 |
Why?
| | Positron-Emission Tomography | 1 | 2019 | 288 | 0.560 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 232 | 0.530 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 253 | 0.510 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2061 | 0.470 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 964 | 0.420 |
Why?
| | Angiogenesis Inhibitors | 1 | 2013 | 220 | 0.360 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 297 | 0.360 |
Why?
| | Survival Rate | 3 | 2020 | 1877 | 0.240 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 16 | 0.220 |
Why?
| | Retrospective Studies | 10 | 2025 | 14518 | 0.210 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2023 | 126 | 0.200 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2004 | 0.170 |
Why?
| | Humans | 19 | 2025 | 129652 | 0.160 |
Why?
| | Treatment Outcome | 5 | 2025 | 10230 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2025 | 759 | 0.160 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2020 | 77 | 0.160 |
Why?
| | Disease-Free Survival | 2 | 2020 | 648 | 0.160 |
Why?
| | Standard of Care | 1 | 2020 | 72 | 0.160 |
Why?
| | Transplantation, Autologous | 1 | 2020 | 211 | 0.160 |
Why?
| | Transplantation Conditioning | 1 | 2020 | 166 | 0.150 |
Why?
| | Transplantation, Homologous | 1 | 2020 | 401 | 0.150 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 7 | 0.150 |
Why?
| | Remission Induction | 1 | 2019 | 272 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 759 | 0.150 |
Why?
| | Autografts | 1 | 2017 | 42 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1565 | 0.140 |
Why?
| | Immune Tolerance | 1 | 2019 | 355 | 0.130 |
Why?
| | Precision Medicine | 1 | 2020 | 387 | 0.130 |
Why?
| | Immunotherapy | 1 | 2020 | 592 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 522 | 0.120 |
Why?
| | Aged | 5 | 2025 | 22104 | 0.120 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2014 | 21 | 0.120 |
Why?
| | Prognosis | 2 | 2023 | 3794 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2025 | 7086 | 0.110 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 81 | 0.110 |
Why?
| | Recurrence | 1 | 2017 | 1007 | 0.110 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2013 | 28 | 0.110 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 634 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1004 | 0.100 |
Why?
| | Cardiotoxins | 1 | 2013 | 4 | 0.100 |
Why?
| | Gene Dosage | 1 | 2013 | 143 | 0.100 |
Why?
| | Middle Aged | 5 | 2025 | 31155 | 0.100 |
Why?
| | Medication Therapy Management | 1 | 2013 | 72 | 0.100 |
Why?
| | Adult | 5 | 2025 | 35577 | 0.090 |
Why?
| | Carcinoma, Renal Cell | 1 | 2013 | 180 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 399 | 0.090 |
Why?
| | Adolescent | 3 | 2020 | 20394 | 0.090 |
Why?
| | Atherosclerosis | 1 | 2014 | 402 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 530 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2014 | 663 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2018 | 4897 | 0.080 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 350 | 0.080 |
Why?
| | Patient Care Team | 1 | 2013 | 605 | 0.070 |
Why?
| | Male | 5 | 2025 | 63682 | 0.070 |
Why?
| | Female | 5 | 2025 | 68777 | 0.070 |
Why?
| | Transcription Factors | 1 | 2014 | 1651 | 0.060 |
Why?
| | Benzodiazepines | 1 | 2025 | 136 | 0.060 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2024 | 85 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2024 | 115 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2024 | 120 | 0.050 |
Why?
| | Inflammation | 1 | 2014 | 2736 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2024 | 105 | 0.050 |
Why?
| | Signal Transduction | 2 | 2014 | 4925 | 0.050 |
Why?
| | Young Adult | 1 | 2018 | 12427 | 0.050 |
Why?
| | Bleomycin | 1 | 2023 | 244 | 0.050 |
Why?
| | Ki-1 Antigen | 1 | 2021 | 4 | 0.050 |
Why?
| | Vincristine | 1 | 2021 | 109 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2021 | 232 | 0.040 |
Why?
| | Rituximab | 1 | 2021 | 164 | 0.040 |
Why?
| | Prednisone | 1 | 2021 | 233 | 0.040 |
Why?
| | Allografts | 1 | 2020 | 136 | 0.040 |
Why?
| | Doxorubicin | 1 | 2021 | 325 | 0.040 |
Why?
| | Canada | 1 | 2020 | 350 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1587 | 0.040 |
Why?
| | Comorbidity | 1 | 2023 | 1547 | 0.040 |
Why?
| | Incidence | 1 | 2023 | 2644 | 0.030 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 37 | 0.030 |
Why?
| | SOXF Transcription Factors | 1 | 2014 | 16 | 0.030 |
Why?
| | E-Selectin | 1 | 2014 | 54 | 0.030 |
Why?
| | Transcription Initiation, Genetic | 1 | 2014 | 15 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2014 | 87 | 0.030 |
Why?
| | Azepines | 1 | 2014 | 89 | 0.030 |
Why?
| | Sequestosome-1 Protein | 1 | 2013 | 13 | 0.030 |
Why?
| | Acetylation | 1 | 2014 | 246 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2014 | 177 | 0.030 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2013 | 79 | 0.030 |
Why?
| | Triazoles | 1 | 2014 | 152 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2014 | 452 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 2014 | 317 | 0.020 |
Why?
| | Chromatin | 1 | 2014 | 479 | 0.020 |
Why?
| | Base Sequence | 1 | 2013 | 2142 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 945 | 0.020 |
Why?
| | Cohort Studies | 1 | 2020 | 5420 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1198 | 0.020 |
Why?
| | Histones | 1 | 2014 | 588 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2832 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2014 | 749 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2704 | 0.020 |
Why?
| | Prospective Studies | 1 | 2020 | 7133 | 0.020 |
Why?
| | Protein Binding | 1 | 2014 | 2121 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 901 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1418 | 0.020 |
Why?
| | United States | 1 | 2025 | 13903 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2014 | 2871 | 0.020 |
Why?
| | Mice | 2 | 2014 | 16937 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2014 | 4083 | 0.020 |
Why?
| | Macrophages | 1 | 2014 | 1480 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 3215 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2014 | 5440 | 0.010 |
Why?
| | Animals | 2 | 2014 | 35361 | 0.010 |
Why?
|
|
Bair's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|